AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Wiz acquires Dazz for $450 million to strengthen AI-driven cloud security
2
Michael Levitt Analysis: Corona Is Slowing Down, Humanity Will Survive
3
Cyera doubles valuation to $3B with $300M Series D, total funding hits $600M in seven months
4
Mediaocean acquires Innovid for $500M, delisting it from the NYSE
5
TailorMed raises $40 million in equity and debt to help patients access critical medications
More news

Pharmaceuticals

18 stories about Pharmaceuticals
מפעל טבע נתניה

There May Be a Silver Lining to Teva’s Woes

06.11.17|Eli Shimony
Analysts have lowered their target price for Teva following the company's less than stellar third quarter reports, but the company can still turn its luck around with new drugs and a willingness to tighten the belt
מטה טבע פתח תקווה

Allergan Planning Sale of its Teva Stock

01.11.17|Dror Reich and Lilach Baumer
For the third quarter of 2017, Allergan reported an operating loss of $4.02 billion, $1.3 billion of which is due to the depreciation of its Teva securities.
מנכ"ל טבע החדש קור שולץ

New CEO to Take Helm at Troubled Teva Wednesday

31.10.17|Lilach Baumer
The generic drugmaker shed 67% of its market price over the last 12 months
מפעל חברת טבע הר חוצבים ירושלים

Teva's Blockbuster Drug Takes Another Generic Blow

26.10.17|Lilach Baumer
Mylan and European Partner Synthon won U.K. patent case related to Teva's Copaxone
מפעל חברת טבע הר חוצבים ירושלים

Teva Canada Probed by Ontario Government

23.10.17|Lilach Baumer
According to a report by Canadian newspaper Toronto Star the company is under investigation for alleged illegal rebates given to pharmacies to boost sales. A Teva spokesman said the company will cooperate fully with any investigation by the Ontario Ministry of Health.
מימין עודד ליברמן מנכל נוירודרם עם נציגי הרוכשת מיצובישי טנאבה

Mitsubishi Tanabe Pharma Finalizes $1.1 Billion Buy of Israel-Based NeuroDerm

19.10.17|Lilach Baumer
NeuroDerm is looking to bring major change to Parkinson patients with its drug reformulation
default image

Kite Pharma’s Cancer Drug Gets Regulatory Nod

19.10.17|Lilach Baumer
The cancer-treatment company, bought by Gilead Science in August for $11.9 billion, will sell one treatment course of the drug for $373,000
יצחק פטרבורג

Teva Submits Potential Moneymaker Migraine Drug for FDA Approval

18.10.17|Dror Reich and Lilach Baumer
Teva’s patent for its moneymaker multiple sclerosis drug Copaxone expired last year
default image

Lonza to Open Research and Development Center in Israel

10.10.17|Lilach Baumer
The company is looking to boost the research and development projects of its pharma and biotech division
אמיר וייסברג

Drug Conduction Company Prepares for Nasdaq IPO

08.10.17|Golan Hazani
Clinical stage PolyPid develops technology for the predetermined, controlled and localized release of drugs at a targeted site
חברת ה תרופות טבע Teva

Teva’s Stock Drops After Approval of Copaxone Competitors

08.10.17|Lilach Baumer
A day after Mylan announced FDA approval for its generic versions of Copaxone, drug companies Synthon and Alvogen announce European approval for their 40 mg/ml generic versions of Teva's blockbuster drug
default image

Pharma Companies Arcturus Therapeutics and Alcobra to Merge

28.09.17|Lilach Baumer
The merged entity will develop treatments for infectious diseases, cystic fibrosis, and rare liver diseases
MeMed מכשיר לזיהוי זיהום ב דם

Automated Medical Diagnosis Startup Raises $30 Million

19.09.17|Omer Kabir
Israel-based MeMed develops an automated blood testing device that can distinguish between bacterial and viral infections. The company previously raised funds from the U.S. Department of Defense
חברת ה תרופות טבע Teva

Teva Sells Remaining Women's Health Assets

18.09.17|Lilach Baumer
After selling its Paragard business for $1.1 billion last week, Teva's remaining Women's Health business will be split between CVC Capital Partners and Foundation Consumer Healthcare in a $1.38 billion cash deal
מפעל חברת טבע הר חוצבים ירושלים

Teva Negotiating Sale of Remaining Women's Health Assets, Report Says

14.09.17|Lilach Baumer
CVC Capital Partners is nearing a $800 million deal for Teva's remaining Women's Health business, Bloomberg reported Thursday
default image

IPO Hopeful Entera Bio Moves to Better Position

13.09.17|Dror Reich
Clinical-stage company Entera Bio develops pioneering technology for orphan disease hypoparathyroidism
מנכ"ל טבע החדש קור שולץ

The Ten Challenges Facing Teva's New CEO

12.09.17|Sophie Shulman
Kåre Schultz is the right man for the job, but he's facing multiple problems, from a changing market to a problematic board
קור שולץ מנכ"ל טבע החדש

Teva Appoints Lundbeck's Schultz as CEO

11.09.17|Dror Reich and Micky Grunfeld
The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated
Previous Articles